SPC waiver proposal could discourage innovation, says pharma group
09-08-2018
AG opines on ‘thorny issue’ in Truvada SPC clash
25-04-2018
English High Court refers Truvada SPC case to CJEU
16-01-2017
sprng23 / iStockphoto.com
Earlier today, the Court of Justice of the European Union (CJEU) clarified when a product is ‘protected by a basic patent’ within the meaning of article 3(a) of regulation 469/2009 (the SPC regulation).
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
CJEU, Court of Justice of the European Union, SPC, Truvada, Teva, Accord Healthcare, Lupin, Mylan, Gilead, patent, supplementary protection certificate
